Related Experiment Video

Updated: May 22, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Cancer and viruses: a double-edged sword

Aisha Q Butt1, Sinéad M Miggin

  • 1Immune Signalling Group, Institute of Immunology, Department of Biology, National University of Ireland Maynooth, Co. Kildare, Ireland.

Proteomics
|May 25, 2012
PubMed

Insights

Oncoviruses cause cancer, but oncolytic viruses can kill cancer cells. This review explores the dual role of tumor viruses and the potential of oncolytic virotherapy, aided by proteomics.

Area of Science:

  • Oncology
  • Virology
  • Immunology
  • Proteomics

Background:

  • Oncoviruses are tumor viruses linked to 11% of cancer deaths.
  • Oncolytic viruses selectively infect and destroy cancer cells.
  • The role of viruses in cancer is complex, acting as both a cause and potential treatment.

Purpose of the Study:

  • To review the neoplastic potential of human tumor-associated viruses.
  • To discuss the therapeutic applications of oncolytic viruses in cancer treatment.
  • To highlight the role of proteomics in understanding oncovirology and immune responses.

Main Methods:

  • Literature review of oncovirology and oncolytic virus research.
  • Analysis of proteomics applications in studying virus-cancer interactions.
  • Summary of vaccine successes and therapeutic strategies.

Main Results:

  • Seven human oncoviruses are identified, associated with various cancers.
  • Numerous oncolytic viruses demonstrate significant potential for cancer therapy.
  • Proteomics offers insights into the interplay between oncoviruses, tumors, and the immune system.

Conclusions:

  • Viruses present a double-edged sword in cancer, causing it and offering treatment possibilities.
  • Oncolytic virotherapy holds promise for diverse cancer interventions.
  • Proteomics is a powerful tool for advancing oncovirology research and developing novel therapies.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Protocols for Investigating the Host-tissue Distribution, Transmission-mode, and Effect on the Host Fitness of a Densovirus in the Cotton Bollworm11:12

Protocols for Investigating the Host-tissue Distribution, Transmission-mode, and Effect on the Host Fitness of a Densovirus in the Cotton Bollworm

Published on: April 12, 2017

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...